At the IGTP TODAY

News

- Research

A novel method for combining laboratory work into a systems biology mathematical model unravels possible mechanisms for the failure of glucocorticoid therapy in ulcerative colitis

Researchers from the Digestive Inflammatory Pathology Research Group at the IGTP and the Spanish Network for Hepatic and Digestive Diseases (CIBEREHD) have identified key elements of the mechanism behind the failure of steroid treatments for ulcerative colitis in some patients. Treatment failure is one of the main obstacles in the management of this disease and the new findings could help prevent treatment failure and allow for more efficient rescue therapies when needed. The study also identifies a possible biomarker to predict which patients might suffer treatment failure.  The research was led by Dr. Eugeni Domènech and Dr. Josep Manyé, and published recently in the Journal of Crohn's and Colitis.

- Research

GCAT publishes its first results on a variety of diseases

Dr Rafael de Cid joined the institute in 2012 as the Scientific Director of the GCAT. Since then, the Project has been successfully set up and is now seeing the first research results. We asked him about the six publications that have appeared so far this year and what GCAT has in the pipeline.

- Campus Can Ruti, Research

The IGTP and the ICO join forces with the IRONMAN Project, the largest international registry for research into metastatic prostate cancer

The Urological Tumour Group of the Catalan Institute of Oncology (ICO-B·ARGO) at the Germans Trias i Pujol Research Institute (IGTP) led by Dr Albert Font Pous in collaboration with the Urology and Radiology Service at the Germans Trias i Pujol Hospital have joined the IRONMAN Project this November.   The project was created and is being mainly financed by the Movember Foundation.

- Innovation, Projects, Research

A project on diagnostics and clinical management of tuberculosis, led by the IGTP, receives Marie Skłodowska Curie Funding

The project, called "Innovation in Tuberculosis - INNOVA4TB", is promoted and coordinated by the research group Innovation in Respiratory Infections and Tuberculosis Diagnosis, led by Dr Jose Domínguez and Dr Cristina Prat.  The proposal has received more than a million euros in funding from the 2018 call for Marie Skłodowska-Curie (MSCA) actions

- Research

Understanding multimorbidity to improve its prevention

In a recent collaborative work, led by researchers from IDIBELL-ICO (ProCURE, Oncobell programs), IDIAP Jordi Gol and GCAT (Genomes of Life, IGTP), the main diseases and associations that contribute significantly to the appearance of multimorbidity are identified. The study also points out inherited genetic factors that have an influence on the appearance of multimorbidity

- Research

Pere-Joan Cardona enters the Royal European Academy of Doctors

Pere-Joan Cardona is a physician specialized in microbiology and parasitology and leader of the Experimental Tuberculosis Unit, which has been researching tuberculosis for 20 years at the Germans Trias i Pujol Research Institute (IGTP).  Cardona was sworn in as full academician of the Royal European Academy of Doctors (RAED) on Tuesday in a ceremony in the auditorium at Fomento de Trabajo Nacional in Barcelona.  Emili Gironella Masgrau made the formal proposal speech.

- Research

Non-invasive stent monitoring techniques tested

Researchers have developed a new non-invasive probe to detect the presence of metallic stents and monitor their potential structural failures in models of coronary artery disease. The new probe, which has been successfully tested on a murine model, would enable the substitution of surgical controls in patients with stents with a simple outpatient procedure. The study results from a collaboration between researchers from the Germans Trias i Pujol Research Institute (IGTP), the University of Barcelona (UB) and Universitat Politècnica de Catalunya (UPC).

- Research

New IGTP spin-off to develop gene therapy for Friedreich’s ataxia, a rare neurodegenerative disease

Biointaxis, the new spin-off company of the IGTP, was recently constituted. The company stems from research led by Dr Antoni Matilla-Dueñas together with Dr Ivelisse Sánchez of the Neurogenetics Group of the IGTP and has been created to increase translational research leading to treatments and new genomic technologies for rare neurological diseases with genetic causes.  The first project the company is undertaking is the development of a gene therapy for Friedreich's Ataxia.